NNNN — Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Company profile

• Sector: Healthcare
• Industry: Medical - Instruments & Supplies
• Country: DE
• Exchange: NASDAQ
• Employees: 27
• Website: https://www.anbio.com

Latest SEC filings for NNNN

• F-3ASR — 2026-07-09
• 6-K — 2026-05-19
• 6-K — 2026-04-27
• 20-F/A — 2026-04-09
• 20-F — 2026-04-07
• 6-K — 2026-02-17
• 6-K — 2026-01-26
• 6-K — 2025-12-30
• 6-K — 2025-11-13

Abrir análisis completo

Educational tool only — not investment advice.